Adamis Pharmaceuticals Operating Income

Adamis Pharmaceuticals (ADMP) currently reports a operating income of $-25M as of September 2023. That compares with $-26M in the prior-year period — up 2.4% year over year. Use the charts on this page to explore Adamis Pharmaceuticals's operating income history and peer comparisons.

Adamis Pharmaceuticals's operating income increased from $-26M to $-25M — a 2.4% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adamis Pharmaceuticals reported $-25M in operating income as of September 2023. That compares with $-26M in the prior-year period — up 2.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-25M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adamis Pharmaceuticals, and consider following ADMP for alerts when major investors trade the stock.

Adamis Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-25M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADMP with unrelated industries.